Improved overall survival and mortality in head and neck cancer with adjuvant concurrent chemoradiotherapy in national databases

被引：35

作者：

Lin, Sonia S. ^{[1
]}

Massa, Sean T. ^{[1
]}

Varvares, Mark A. ^{[2
]}

机构：

[1] Univ S Carolina, Keck Sch Med, Dept Internal Med, Los Angeles, CA USA

[2] St Louis Univ, Ctr Canc, Sch Med, Dept Otolaryngol Head & Neck Surg, St Louis, MO 63103 USA

来源：

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2016年 / 38卷 / 02期

关键词：

head and neck cancer; overall survival; reduced mortality; adjuvant chemoradiotherapy; concurrent chemoradiotherapy; SQUAMOUS-CELL CARCINOMA; LOCALLY ADVANCED HEAD; FREE-FLAP RECONSTRUCTION; NODE-POSITIVE HEAD; ORAL-CAVITY CANCER; POSTOPERATIVE RADIOTHERAPY; HUMAN-PAPILLOMAVIRUS; RADIATION-THERAPY; OROPHARYNGEAL CANCER; PATIENT SURVIVAL;

D O I：

10.1002/hed.23869

中图分类号：

R76 [耳鼻咽喉科学];

学科分类号：

100213 ;

摘要：

BackgroundMany studies have demonstrated the advantage of postoperative concurrent chemoradiotherapy (CRT) over radiotherapy (RT) alone in locoregional control, but few have examined overall survival with respect to national databases. MethodsThe literature was searched for eligible randomized controlled trials. The Surveillance, Epidemiology, and End Results (SEER) Database and National Cancer Data Base (NCDB) were searched for 5-year overall survival data. ResultsTwenty-eight studies were examined and demonstrated 44% greater locoregional control (relative risk [RR]=0.56; 95% confidence interval [CI]=0.46-0.68) and 12% overall survival benefit (RR=0.88; 95% CI=0.81-0.98) with postoperative adjuvant CRT compared to adjuvant RT. Overall SEER survival was 45.0% in 1973, rising to 53.2% in 2005. The NCDB documents a similar increase in overall survival from 45.5% in 1994 to 53.4% in 2005. ConclusionThe literature shows mortality benefit of adjuvant CRT in patients with advanced head and neck cancer, reflected in SEER and NCDB. (c) 2015 Wiley Periodicals, Inc. Head Neck 38: 208-215, 2016

引用

页码：208 / 215

页数：8

共 50 条

[31] Classical risk factors, but not HPV status, predict survival after chemoradiotherapy in advanced head and neck cancer patients [J].

Descamps, Geraldine ;

Karaca, Yasemin ;

Lechien, Jerome R. ;

Kindt, Nadege ;

Decaestecker, Christine ;

Remmelink, Myriam ;

Larsimont, Denis ;

Andry, Guy ;

Hassid, Samantha ;

Rodriguez, Alexandra ;

Khalife, Mohammad ;

Journe, Fabrice ;

Saussez, Sven .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2016, 142 (10) :2185-2196

[32] Concurrent chemoradiotherapy in adjuvant treatment of breast cancer [J].

Nabil Ismaili ;

Nawfel Mellas ;

Ouafae Masbah ;

Sanaa Elmajjaoui ;

Samia Arifi ;

Imane Bekkouch ;

Samir Ahid ;

Zakaria Bazid ;

Mohammed Adnane Tazi ;

Abdelouahed Erraki ;

Omar El Mesbahi ;

Noureddine Benjaafar ;

Brahim El Khalil El Gueddari ;

Mohammed Ismaili ;

Said Afqir ;

Hassan Errihani .

Radiation Oncology, 4

[33] Immunotherapy of Head and Neck Cancer: Emerging Clinical Trials From a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting [J].

Bauman, Julie E. ;

Cohen, Ezra ;

Ferris, Robert L. ;

Adelstein, David J. ;

Brizel, David M. ;

Ridge, John A. ;

O'Sullivan, Brian ;

Burtness, Barbara A. ;

Butterfield, Lisa H. ;

Carson, William E. ;

Disis, Mary L. ;

Fox, Bernard A. ;

Gajewski, Thomas F. ;

Gillison, Maura L. ;

Hodge, James W. ;

Quynh-Thu Le ;

Raben, David ;

Strome, Scott E. ;

Lynn, Jean ;

Malik, Shakun .

CANCER, 2017, 123 (07) :1259-1271

[34] Concurrent chemoradiotherapy in adjuvant treatment of breast cancer [J].

Ismaili, Nabil ;

Mellas, Nawfel ;

Masbah, Ouafae ;

Elmajjaoui, Sanaa ;

Arifi, Samia ;

Bekkouch, Imane ;

Ahid, Samir ;

Bazid, Zakaria ;

Tazi, Mohammed Adnane ;

Erraki, Abdelouahed ;

El Mesbahi, Omar ;

Benjaafar, Noureddine ;

El Gueddari, Brahim El Khalil ;

Ismaili, Mohammed ;

Afqir, Said ;

Errihani, Hassan .

RADIATION ONCOLOGY, 2009, 4

[35] Statin use associated with improved overall and cancer specific survival in patients with head and neck cancer [J].

Gupta, Abhinav ;

Stokes, William ;

Eguchi, Megan ;

Hararah, Mohammad ;

Amini, Arya ;

Mueller, Adam ;

Morgan, Rustain ;

Bradley, Cathy ;

Raben, David ;

McDermott, Jessica ;

Karam, Sana D. .

ORAL ONCOLOGY, 2019, 90 :54-66

[36] Concurrent hyperfractionated chemoradiotherapy for head and neck squamous cell carcinoma: the prognostic impact of the overall treatment time and completion rates of chemotherapy [J].

Fujii, Masami ;

Ohguri, Takayuki ;

Yahara, Katsuya ;

Imada, Hajime ;

Tomura, Kyosuke ;

Sakagami, Mai ;

Nagatani, Gunji ;

Suzuki, Hideaki ;

Korogi, Yukunori .

SPRINGERPLUS, 2015, 4

[37] Treatment Outcomes and Prognostic Factors of Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and Fluorouracil in Advanced Head and Neck Cancer [J].

Kusaka, Takahiro ;

Shiga, Kiyoto ;

Katagiri, Katsunori ;

Saito, Daisuke ;

Oikawa, Shin-ichi ;

Ikeda, Aya ;

Tsuchida, Kodai ;

Miyaguchi, Jun ;

Ohashi, Yu ;

Ariga, Hisanori ;

Tanno, Kozo .

ANTICANCER RESEARCH, 2022, 42 (12) :6047-6056

[38] A Phase I Study of Concurrent Chemoradiotherapy Using Oral S-1 for Head and Neck Cancer [J].

Fujimoto, Yasushi ;

Kato, Satoshi ;

Itoh, Yoshiyuki ;

Naganawa, Shinji ;

Nakashima, Tsutomu .

ANTICANCER RESEARCH, 2014, 34 (1A) :209-213

[39] Risk factors for aspiration pneumonia during concurrent chemoradiotherapy or bio-radiotherapy for head and neck cancer [J].

Shirasu, Hiromichi ;

Yokota, Tomoya ;

Hamauchi, Satoshi ;

Onozawa, Yusuke ;

Ogawa, Hirofumi ;

Onoe, Tsuyoshi ;

Onitsuka, Tetsuro ;

Yurikusa, Takashi ;

Mori, Keita ;

Yasui, Hirofumi .

BMC CANCER, 2020, 20 (01)

[40] Concurrent chemoradiotherapy for head neck cancers. Should organs at risk dose constraints be revisited? [J].

Lapeyre, M. ;

Biau, J. ;

Miroir, J. ;

Moreau, J. ;

Gleyzolle, B. ;

Brun, L. ;

Racadot, S. ;

Graff-Cailleaud, P. .

CANCER RADIOTHERAPIE, 2020, 24 (6-7) :586-593

← 1 2 3 4 5 →